New pill aims to turn Body's defenses against rare, tough cancers
NCT ID NCT07014137
Summary
This study is testing an experimental oral drug, ABSK043, in about 20 adults with advanced forms of a rare cancer called angiogenic sarcoma. The drug works by blocking a protein that can hide cancer cells from the immune system, potentially helping the body fight the cancer. The main goals are to see if the drug shrinks tumors, is safe for patients, and to find biological signs that predict who might benefit most.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHN- Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.